Can you explain the Gleason scoring system and what the notation 3‑4‑5 indicates?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Understanding the Gleason Score Notation 3-4-5

The notation "3-4-5" in Gleason scoring represents a three-part grading system where 3 is the most predominant cancer pattern, 4 is the second most predominant pattern, and 5 is a tertiary (minor) high-grade pattern present in the tumor. 1

How the Gleason Score is Constructed

The Gleason grading system assigns grades from 1 (least aggressive) to 5 (most aggressive) based on the architectural differentiation of prostate cancer cells under microscopic examination. 1

Standard two-pattern scoring:

  • The pathologist identifies the primary grade (most predominant pattern) and secondary grade (second most predominant pattern) 1
  • These two grades are added together to create the Gleason score (e.g., 3+4=7) 1
  • An important exception: if the highest grade pattern is neither the most nor second most predominant, it replaces the secondary grade in the score 1

Three-pattern notation (tertiary grade):

  • When a small component of tumor shows a pattern higher than the two most predominant patterns, it is reported as a tertiary grade 1
  • Example: If a tumor contains 60% pattern 3,35% pattern 4, and 5% pattern 5, it should be reported as "3+4 with tertiary grade 5" 1
  • This can also be displayed as "3-4-5" where the tertiary pattern is explicitly noted 1

Clinical Significance of Tertiary Patterns

Tumors with a tertiary Gleason grade 4 or 5 behave more aggressively than the sum of the two dominant patterns alone would suggest. 2 This is critical because:

  • A Gleason score 3+4=7 with tertiary grade 5 carries worse prognosis than 3+4=7 without tertiary pattern 2
  • The presence of any pattern 5, even if focal, indicates more aggressive disease 3
  • This information directly impacts risk stratification and treatment planning 2, 4

Modern Grade Group Classification

The International Society of Urological Pathology introduced a simplified system that correlates with Gleason scores: 2, 3

  • Grade Group 1: Gleason ≤6 (only well-formed glands) 2
  • Grade Group 2: Gleason 3+4=7 (predominantly well-formed glands) 2
  • Grade Group 3: Gleason 4+3=7 (predominantly poorly formed glands) 2
  • Grade Group 4: Gleason 8 (only poorly formed glands) 2
  • Grade Group 5: Gleason 9-10 (lack of gland formation) 2

Risk Stratification Impact

With each increase in Gleason score, there is a measurable increase in tumor aggressiveness and worse clinical outcomes. 1

The presence of pattern 5 as a tertiary grade elevates the tumor to high-risk category: 2, 4

  • High Risk definition: Gleason score 8-10 OR PSA >20 ng/mL OR clinical stage T3-T4 2
  • 5-year biochemical recurrence-free survival for Grade Group 5: 26% 2
  • Treatment requirement: Aggressive definitive treatment is mandatory if life expectancy ≥5 years 4

Common Pitfalls

Critical distinction: Gleason 4+3=7 carries significantly worse prognosis than 3+4=7, despite both summing to 7. 1, 5 The order matters because it reflects which pattern is dominant.

Biopsy limitations: Needle biopsies underestimate tumor grade in 33-45% of cases due to sampling error and tumor heterogeneity. 6 The tertiary pattern may be missed on biopsy but found at prostatectomy.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Prostate Cancer Risk Assessment Based on Gleason Score

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Prostate Cancer Grading and Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Grading prostate cancer.

American journal of clinical pathology, 1994

Related Questions

What is the Gleason classification in prostate cancer for a male patient over 50 with a family history of prostate cancer?
What is the best way to explain the Gleason score to a patient with prostate cancer?
How do I explain a Gleason score of 3+4 to a patient with moderately aggressive prostate cancer?
What is the treatment approach for a patient with prostate cancer having a Gleason score of 7 (4+3) and 12 out of 18 biopsy cores containing cancer, with low consideration for External Beam Radiation Therapy (XRT)?
What is the best treatment option for a patient with a PSA of 9, Gleason score 3+4, and localized prostate cancer with no lymph node involvement or distant metastasis, considering radical radiotherapy or robotic prostatectomy?
What is the recommended treatment for a previously healthy 6‑year‑old boy with confirmed or suspected influenza A?
In a smoker with a cold thyroid nodule, poorly defined ultrasound margins, unilateral cervical lymphadenopathy, dysphagia, hoarseness, fatigue, and loss of appetite, what is the most likely diagnosis and what diagnostic work‑up and treatment plan should be pursued?
What is the recommended duration and dosing schedule of oral vancomycin for a first episode of Clostridioides difficile infection and for first or subsequent recurrences?
Can a diabetic patient on insulin or sulfonylurea develop hypotension secondary to severe hypoglycemia?
What is the recommended COVID‑19 treatment for an elderly, morbidly obese, bed‑bound female nursing‑home resident with mild upper‑respiratory symptoms (sore throat and myalgia)?
What is the recommended treatment regimen for a chronic lymphocytic leukemia (CLL) patient who will receive acalabrutinib 100 mg twice daily (bid) for 14 cycles and start venetoclax in cycle 3?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.